242 related articles for article (PubMed ID: 31973227)
21. Finding Potent Sirt Inhibitor in Coffee: Isolation, Confirmation and Synthesis of Javamide-II (N-Caffeoyltryptophan) as Sirt1/2 Inhibitor.
Park JB
PLoS One; 2016; 11(3):e0150392. PubMed ID: 26986569
[TBL] [Abstract][Full Text] [Related]
22. Expression of sirtuin 1 and 2 is associated with poor prognosis in non-small cell lung cancer patients.
Grbesa I; Pajares MJ; Martínez-Terroba E; Agorreta J; Mikecin AM; Larráyoz M; Idoate MA; Gall-Troselj K; Pio R; Montuenga LM
PLoS One; 2015; 10(4):e0124670. PubMed ID: 25915617
[TBL] [Abstract][Full Text] [Related]
23. The discovery of a highly selective 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one SIRT2 inhibitor that is neuroprotective in an in vitro Parkinson's disease model.
Di Fruscia P; Zacharioudakis E; Liu C; Moniot S; Laohasinnarong S; Khongkow M; Harrison IF; Koltsida K; Reynolds CR; Schmidtkunz K; Jung M; Chapman KL; Steegborn C; Dexter DT; Sternberg MJ; Lam EW; Fuchter MJ
ChemMedChem; 2015 Jan; 10(1):69-82. PubMed ID: 25395356
[TBL] [Abstract][Full Text] [Related]
24. Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes.
Heltweg B; Gatbonton T; Schuler AD; Posakony J; Li H; Goehle S; Kollipara R; Depinho RA; Gu Y; Simon JA; Bedalov A
Cancer Res; 2006 Apr; 66(8):4368-77. PubMed ID: 16618762
[TBL] [Abstract][Full Text] [Related]
25. Selective SIRT2 inhibitors as promising anticancer therapeutics: An update from 2016 to 2020.
Roshdy E; Mustafa M; Shaltout AE; Radwan MO; Ibrahim MAA; Soliman ME; Fujita M; Otsuka M; Ali TFS
Eur J Med Chem; 2021 Nov; 224():113709. PubMed ID: 34303869
[TBL] [Abstract][Full Text] [Related]
26. Identification of a Selective SIRT2 Inhibitor and Its Anti-breast Cancer Activity.
Shah AA; Ito A; Nakata A; Yoshida M
Biol Pharm Bull; 2016; 39(10):1739-1742. PubMed ID: 27725455
[TBL] [Abstract][Full Text] [Related]
27. Direct Comparison of SIRT2 Inhibitors: Potency, Specificity, Activity-Dependent Inhibition, and On-Target Anticancer Activities.
Spiegelman NA; Price IR; Jing H; Wang M; Yang M; Cao J; Hong JY; Zhang X; Aramsangtienchai P; Sadhukhan S; Lin H
ChemMedChem; 2018 Sep; 13(18):1890-1894. PubMed ID: 30058233
[TBL] [Abstract][Full Text] [Related]
28. Structure activity study of S-trityl-cysteamine dimethylaminopyridine derivatives as SIRT2 inhibitors: Improvement of SIRT2 binding and inhibition.
Radwan MO; Ciftci HI; Ali TFS; Koga R; Tateishi H; Nakata A; Ito A; Yoshida M; Fujita M; Otsuka M
Bioorg Med Chem Lett; 2020 Oct; 30(19):127458. PubMed ID: 32755678
[TBL] [Abstract][Full Text] [Related]
29. Development of 1,2,4-Oxadiazoles as Potent and Selective Inhibitors of the Human Deacetylase Sirtuin 2: Structure-Activity Relationship, X-ray Crystal Structure, and Anticancer Activity.
Moniot S; Forgione M; Lucidi A; Hailu GS; Nebbioso A; Carafa V; Baratta F; Altucci L; Giacché N; Passeri D; Pellicciari R; Mai A; Steegborn C; Rotili D
J Med Chem; 2017 Mar; 60(6):2344-2360. PubMed ID: 28240897
[TBL] [Abstract][Full Text] [Related]
30. Javamide-I-O-methyl ester increases p53 acetylation and induces cell death via activating caspase 3/7 in monocytic THP-1 cells.
Park JB
Phytomedicine; 2016 Dec; 23(13):1647-1652. PubMed ID: 27823629
[TBL] [Abstract][Full Text] [Related]
31. Discovery of a potent small molecule SIRT1/2 inhibitor with anticancer effects.
Choi G; Lee J; Ji JY; Woo J; Kang NS; Cho SY; Kim HR; Ha JD; Han SY
Int J Oncol; 2013 Oct; 43(4):1205-11. PubMed ID: 23900402
[TBL] [Abstract][Full Text] [Related]
32. Pharmacophore modeling and virtual screening studies to identify novel selective SIRT2 inhibitors.
Eren G; Bruno A; Guntekin-Ergun S; Cetin-Atalay R; Ozgencil F; Ozkan Y; Gozelle M; Kaya SG; Costantino G
J Mol Graph Model; 2019 Jun; 89():60-73. PubMed ID: 30870650
[TBL] [Abstract][Full Text] [Related]
33. Structure-based design of pseudopeptidic inhibitors for SIRT1 and SIRT2.
Huhtiniemi T; Salo HS; Suuronen T; Poso A; Salminen A; Leppänen J; Jarho E; Lahtela-Kakkonen M
J Med Chem; 2011 Oct; 54(19):6456-68. PubMed ID: 21895016
[TBL] [Abstract][Full Text] [Related]
34. 5-((3-Amidobenzyl)oxy)nicotinamides as SIRT2 Inhibitors: A Study of Constrained Analogs.
Ai T; Wilson DJ; Chen L
Molecules; 2023 Nov; 28(22):. PubMed ID: 38005376
[TBL] [Abstract][Full Text] [Related]
35. Functional characterization of NAD dependent de-acetylases SIRT1 and SIRT2 in B-Cell Chronic Lymphocytic Leukemia (CLL).
Bhalla S; Gordon LI
Cancer Biol Ther; 2016; 17(3):300-9. PubMed ID: 26794150
[TBL] [Abstract][Full Text] [Related]
36. Novel small molecule SIRT2 inhibitors induce cell death in leukemic cell lines.
Kozako T; Mellini P; Ohsugi T; Aikawa A; Uchida YI; Honda SI; Suzuki T
BMC Cancer; 2018 Aug; 18(1):791. PubMed ID: 30081901
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and Evaluation of Novel Benzofuran Derivatives as Selective SIRT2 Inhibitors.
Zhou Y; Cui H; Yu X; Peng T; Wang G; Wen X; Sun Y; Liu S; Zhang S; Hu L; Wang L
Molecules; 2017 Aug; 22(8):. PubMed ID: 28805748
[TBL] [Abstract][Full Text] [Related]
38. Modulation Of Microtubule Acetylation By The Interplay Of TPPP/p25, SIRT2 And New Anticancer Agents With Anti-SIRT2 Potency.
Szabó A; Oláh J; Szunyogh S; Lehotzky A; Szénási T; Csaplár M; Schiedel M; Lőw P; Jung M; Ovádi J
Sci Rep; 2017 Dec; 7(1):17070. PubMed ID: 29213065
[TBL] [Abstract][Full Text] [Related]
39. Design, synthesis, in-vitro evaluation and molecular docking studies of novel indole derivatives as inhibitors of SIRT1 and SIRT2.
Manjula R; Gokhale N; Unni S; Deshmukh P; Reddyrajula R; Srinivas Bharath MM; Dalimba U; Padmanabhan B
Bioorg Chem; 2019 Nov; 92():103281. PubMed ID: 31561106
[TBL] [Abstract][Full Text] [Related]
40. CHM-1, a novel microtubule-destabilizing agent exhibits antitumor activity via inducing the expression of SIRT2 in human breast cancer cells.
Liu CW; Lin YC; Hung CM; Liu BL; Kuo SC; Ho CT; Way TD; Hung CH
Chem Biol Interact; 2018 Jun; 289():98-108. PubMed ID: 29679549
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
